Diarrhea is one of the most commonly reported adverse effect of hemotherapy and targeted cancer therapies, such as tyrosine kinase inhibitors (TKI), which often significantly impact patient quality of life, morbidity, and mortality. Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor, which is clinically active in HER2-positive breast cancer. Diarrhea is the most common side effect of this potent antican- 
tive breast cancer. Diarrhea is the most common side effect of this potent anticancer drug and the reasons for this adverse effect are still largely unclear. We have recently shown that activation of the calcium-sensing Receptor (CaSR) can inhibit secretagogue-induced diarrhea in the colon, therefore we hypothesized that CaSR activation may also mitigate neratinib-induced diarrhea. Using an established ex vivo model of isolated intestinal segments, we investigated neratinib-induced fluid secretion and the ability of CaSR activation to abate the secretion. In our study, individual segments of the rat intestine (proximal, middle, distal small intestine, and colon) were procured and perfused intraluminally with various concentrations of neratinib (10, 
| INTRODUC TI ON
Neratinib (PB-272; also called HKI-272, Nerlynx™) is an oral anticancer drug, which has clinical activity in HER2-positive breast cancer 1 and is the first anticancer drug approved by the US FDA for extended adjuvant treatment of early stage of this type of cancer following trastuzumab therapy. The mechanism of action of neratinib is well studied and described in recent literature. 2, 3 The drug is a potent, small molecule, irreversible tyrosine-kinase inhibitor of human epidermal growth factor receptors (EGFRs, also known as HER-1, ErbB-1), HER2 (neu, ErbB-2), and HER4 (ErbB-4). o ) which binds to the surface of the two large exofacial loops of the receptor leading to activation of the receptor leading to decreases in intestinal secretion, motility, inflammation, and increased ionic and fluid absorption.
In the present study, we hypothesized that the activation of CaSR by elevating luminal intestinal calcium could reduce or abate the neratinib-induced diarrhea. Furthermore, we studied prophylactic pretreatment with oral calcium to prevent neratinib-induced fluid secretion when the drug was given post prophylactics.
| MATERIAL AND ME THODS

| Material
| Animals
The small intestines were harvested from adult male Sprague-Dawley rats (250-365 g body weight, n = 58. All animals were obtained from Charles River Laboratories (Wilmington) and housed in climate-and humidity-controlled 12:12-hour light-dark cycled rooms at the Yale animal facility. All animals were fed standard rodent chow and then fasted for 12-15 hours prior to the study with continued free access to water.
| Perfusion solutions
For our study, we used a Ringer HEPES buffer solution (HEPES solution) with different Ca 2+ concentrations (see Table 1 ) with a final pH of 7.4 at 37°C. For all studies that contained neratinib a final concentration of 100 nmol L −1 was used. This concentration was obtained by diluting a stock solution containing neratinib and Polysorbate 80 (Sigma).
| Reagents used
R-568 hydrochloride was purchased from Sigma-Aldrich. The drug was dissolved in Dimethyl Sulfoxide (DMSO; Sigma-Aldrich).
| FITC-inulin
To quantitatively evaluate secretory-absorptive function of the various intestine segments, we have used the isothiocyanate derivative fluorescein isothiocyanate (FITC) coupled to the nonabsorbable volume marker inulin (hereinafter referred to as "FITC-Inulin"). 27, 28 Inulin is a nonabsorbable sugar with a molecular weight of 3500 Da, which makes it nonpermeable through the intestinal wall. The concentration of FITC-Inulin (Sigma-Aldrich, St. Louis, MO) was 50 µmol L −1 for all arms of this study.
| Intestinal procurement and intestinal perfusion setup
Entire rat small intestine was procured, and three segments were obtained: proximal, middle, and distal each approximately 10 cm in length. outer chamber. The chamber was filled with warm (37°C) buffer solution and then flow was established to the reservoir containing one of the solutions described in Table 1 .
| Calculation of results
Calibration protocol
To calibrate the nanofluorospectrophotometer (Nanodrop 3300, Thermo Fisher Scientific Inc.) for each measurement we performed a series of three standard calibrations curves for each solution that was used as a perfusate. The mean values of these calibration curves were used as the standard curve for that series of studies. Separate calibration curves were conducted for each study and each tissue used.
Experimental sample protocol
Each sample luminal perfusate was composed of FITC-Inulin + the various solutions found in Table 1 with or without neratinib (control). To calculate the value of each particular time point, samples were collected and then measured and plotted on the calibration curve that was generated on that day. We collected five samples for each time point for each tissue, the mean values for that time point were then calculated and plotted as a single data point with the appropriate error bars. Each replicate animal undergoing the same protocol was also added to the accumulated data and the final values for the tracing presented came from the data collected under these same conditions.
| Statistics
All studies presented are calculated for significance and plotted using the GraphPad Prism 7.01 software (GraphPad software Inc.).
All bar graphs are plotted as SD, the p values are calculated using a multiple comparisons ANOVA analyses (n.s. P > 0.05, *P < .05, **P < .01, ***P < .001, ****P < .0001).
| Ethical consideration
The animal handling and procurement of small intestine and colon were performed according to approved protocols of the Animal Care and Use Committee at Yale University (Protocol #2015-10253).
| RE SULTS
| Modulation in luminal Ca
2+ concentration in control conditions
In this series of studies, we measured the changes in fluid secretion with various concentrations of luminal calcium (See Table 1 ) 
at 5°C
Note: The osmolality of all solutions was adjusted to 300 (±5) mOsm.
TA 
| Effects of neratinib on secretory-absorptive functions of colon
Previous studies from our group have shown that the colon also contains an active CaSR that can be stimulated by elevating the Ca 2+ concentration in the lumen, or via exposure to a calcimimetic. 13, 14, 18, 24, 30 In this series using isolated colons from rats we were able to see a rapid and sustained fluid secretion following exposure to increasing doses of neratinib (Figure 4 ). 
| Elevated luminal Ca
| Memory effects of CaSR activation prior to neratinib exposure
Following the positive effects of elevating luminal Ca 2+ to abate neratinib-induced fluid secretion we examined pre-exposure to elevated ) prior to neratinib exposure. As shown in Figure 6A -C, 15 minutes of elevated Ca 2+ followed by a return to Ca 2+ prevented neratinib-sensitive fluid secretion ( Figure 6D ).
| Effects of R-568 (calcimimetic) on neratinib-induced fluid secretion in the small intestine and colon
We next compared the effects of R-568 (400 nmol L −1 ) with a normal 
| D ISCUSS I ON
Targeted therapies such as TKIs are showing promising clinical efficacy in cancer patients, however, the side effects of the therapy can in some cases adverse symptoms that may lead to the cessation of treatment. [31] [32] [33] [34] A very common adverse effect from chemotherapy or certain TKIs, such as neratinib, is diarrhea which can lead to dramatic loss of fluids and electrolytes, and under severe conditions also lead to malabsorption of nutrients due to the accelerated transit time along the intestine.
35,36
In the present study, we investigated if activation of the CaSR either concurrently or prophylactically prior to exposure to neratinib could lead to a reduction in the loss of fluid and electrolytes, which would allow patients an improved quality of life while taking the drug.
| Isolated intestinal segments and fluid secretion
As the small intestine plays an important role in fluid and electrolyte homeostasis, 27,37,38 we wished to first investigate if the previously reported side effect of diarrhea was linked to neratinib having a direct action in the small intestine. Recently, our team has developed an isolated perfusion system that allows us to look at proximal, middle, and distal small intestine while sampling the content of the lumen. 27, 28, 38 The ability to have isolated intestinal 
| Effects of neratinib on fluid secretion in the small intestine
In these studies, we examined and confirmed that exposure to neratinib in the lumen led to a dose-dependent increase in fluid secretion in proximal, middle, and distal segments of the small intestine (See Since there was an increase in the levels of fluid secretion this could not only result in fluid loss but may also cause a reduction in the absorption of electrolytes. 
| Effects of neratinib on fluid secretion in the colon
| Modulation of neratinib-induced fluid secretion in the colon by CaSR activation
The effects of CaSR activation in the colon are well defined by our laboratory regarding secretagogue-induced diarrhea. 13, 15, 23, 39 In this series of experiments, we could show that in the col on as in the small intestine, elevating luminal Ca 2+ abated the neratinib-induced fluid secretion in this segment. This data shows that elevating oral Ca 2+ will give a protective effect to the entire neratinib. The data are the summary of colon segments taken from five rats for each group at 60 minutes exposure to the drug intestine and colon thereby preventing the associated diarrhea while taking the medication. This promising observation now gives a nutraceutical therapy that should have little to no side effects and could be applied at any point of the chemotherapy cycle.
| Memory effects of CaSR activation prior to neratinib exposure
One additional question was whether the beneficial effects of Ca 2+ could be given prior to the neratinib and still maintain the protective antisecretory effect in the gut. We were in the studies shown in Figure 6 able to demonstrate that exposure for 15 minutes to an elevated Ca 2+ solution would be sufficient to maintain the antisecretory effects when Ca 2+ concentration returned to the reduced level and neratinib was added. This observation suggests that a short stimulation of the CaSR can provide a "memory effect" whereby the intestine becomes temporarily resistant to neratinib-induced diarrhea. This is an important finding in that it suggests that a prophylactic dose of Ca 2+ followed by neratinib and Ca 2+ may provide an even more complete prevention. 
| Effects of R-568 (calcimimetic) on neratinib-
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